文献速递消化道肿瘤与早癌

HNF4α通路定位野生型IDH1为胃癌可靶向代谢节点

HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer.
PubMed 文献 · Gut · 2019-05-08

该研究在多种胃癌细胞系中行HNF4α染色质免疫沉淀测序,整合原发胃癌(表观)基因组与转录组数据定义HNF4α靶基因。结果发现HNF4α在胃癌中特异性上调,有机酸代谢为其首要调控通路,野生型IDH1为HNF4α直接靶点且对胃癌细胞生存必需,部分胃癌细胞可被IDH1抑制剂靶向。

要点

  • HNF4α在19种肿瘤类型中仅胃癌特异性上调,有机酸代谢为首要调控通路。
  • 野生型IDH1为HNF4α直接靶点,对胃癌细胞生存必需。
  • 部分胃癌细胞可被IDH1抑制剂靶向。

核心结论

  • HNF4α通过调控IDH1维持胃癌致癌代谢,靶向野生型IDH1的药物可能在HNF4α过表达的胃癌中具有临床价值。

研究设计与样本

  • 在多种胃癌细胞系中行HNF4α染色质免疫沉淀测序,整合原发胃癌(表观)基因组与转录组数据定义HNF4α靶基因;行肿瘤代谢测定、药物治疗及功能实验包括小鼠异种移植实验。

主要发现

  • 19种肿瘤类型的基因表达分析显示HNF4α在胃癌中特异性上调。
  • 无偏通路分析显示有机酸代谢为HNF4α调控的首要通路,代谢组学分析正交支持。
  • 异柠檬酸脱氢酶1(IDH1)为汇聚的HNF4α直接靶基因,调控胃癌代谢。
  • 野生型IDH1对胃癌细胞生存必需,部分胃癌细胞可被IDH1抑制剂靶向。

关键数值与推荐

  • 基因表达分析涵盖19种肿瘤类型,HNF4α在胃癌中特异性上调。

临床怎么用

  • 作者认为靶向野生型IDH1的药物可能在HNF4α过表达的胃癌中具有临床价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gastric cancer (GC) is a leading cause of cancer mortality. Previous studies have shown that hepatocyte nuclear factor-4α (HNF4α) is specifically overexpressed in GC and functionally required for GC development. In this study, we investigated, on a genome-wide scale, target genes of HNF4α and oncogenic pathways driven by HNF4α and HNF4α target genes. DESIGN: We performed HNF4α chromatin immunoprecipitation followed by sequencing across multiple GC cell lines, integrating HNF4α occupancy data with (epi)genomic and transcriptome data of primary GCs to define HNF4α target genes of in vitro and in vivo relevance. To investigate mechanistic roles of HNF4α and HNF4α targets, we performed cancer metabolic measurements, drug treatments and functional assays including murine xenograft experiments. RESULTS: Gene expression analysis across 19 tumour types revealed HNF4α to be specifically upregulated in GCs. Unbiased pathway analysis revealed organic acid metabolism as the top HNF4α-regulated pathway, orthogonally supported by metabolomic analysis. Isocitrate dehydrogenase 1 (IDH1) emerged as a convergent HNF4α direct target gene regulating GC metabolism. We show that wild-type IDH1 is essential for GC cell survival, and that certain GC cells can be targeted by IDH1 inhibitors. CONCLUSIONS: Our results highlight a role for HNF4α in sustaining GC oncogenic metabolism, through the regulation of IDH1. Drugs targeting wild-type IDH1 may thus have clinical utility in GCs exhibiting HNF4α overexpression, expanding the role of IDH1 in cancer beyond IDH1/2 mutated malignancies.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Xu C, Ooi WF, Qamra A, et al. HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. Gut. 2019. PMID: 31068366. doi:10.1136/gutjnl-2018-318025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。